Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Affymetrix OncoScan SNP arrays for profiling somatic copy-number alterations in blastic plasmacytoid dendritic cell neoplasm

ABSTRACT: Affymetrix OncoScan SNP arrays for profiling somatic copy-number alterations in blastic plasmacytoid dendritic cell neoplasm

PROVIDER: PRJNA823007 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Affymetrix OncoScan SNP arrays for profiling somatic copy-number alterations in blastic plasmacytoid dendritic cell neoplasm

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignancy assumed to originate from plasmacytoid dendritic cells (pDCs), which affects the skin and bone marrow and sequentially other organ systems. Here, we used Affymetrix OncoScan CNV arrays to characterize somatic copy number variations in 45 BPDCN cases.

2022-04-05 | GSE200113 | GEO

Methylation data profiling for blastic plasmacytoid dendritic cell neoplasm

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignancy assumed to originate from plasmacytoid dendritic cells (pDCs), which affects the skin and bone marrow and sequentially other organ systems. Here, we used EPIC arrays to characterize methylation profiles in 51 BPDCN cases.

2024-02-11 | GSE230487 | GEO

Genomics of blastic plasmacytoid dendritic cell neoplasm

Project description:Genomics of blastic plasmacytoid dendritic cell neoplasm

| PRJNA944369 | ENA

Genomics of blastic plasmacytoid dendritic cell neoplasm

Project description:Genomics of blastic plasmacytoid dendritic cell neoplasm

| PRJNA944370 | ENA

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to nf-kb pathway inhibition

Project description:Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to nf-kb pathway inhibition

2014-10-03 | GSE62014 | GEO

Methylation data profiling for blastic plasmacytoid dendritic cell neoplasm

Project description:Methylation data profiling for blastic plasmacytoid dendritic cell neoplasm

| PRJNA961200 | ENA

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to nf-kb pathway inhibition

Project description:Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to nf-kb pathway inhibition To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart Raw matrix per probe not available. Raw matrix collapsed by gene available as suppplementary file (GSE62014_non-normalized.txt).

2014-10-03 | E-GEOD-62014 | biostudies-arrayexpress

RUNX2 promotes the development of Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Project description:RUNX2 promotes the development of Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

| PRJNA432940 | ENA

A Druggable TCF4- and BRD4-dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm (ATAC-Seq)

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and largely incurable hematologic malignancy originating from plasmacytoid dendritic cells (pDCs). Using RNA interference screening, we identified the E-box transcription factor TCF4 as a master regulator of the BPDCN oncogenic program. TCF4 served as a faithful diagnostic marker of BPDCN, and its downregulation caused the loss of the BPDCN-specific expression program and apoptosis. High-throughput drug screening revealed that bromodomain and extra-terminal domain inhibitors (BETi's) induce BPDCN apoptosis, which was attributable to disruption of the TCF4-dependent transcriptional network and loss of BPDCN-specific super-enhancers. BETi's retarded the growth of BPDCN xenografts, supporting their clinical evaluation in this recalcitrant malignancy.

2016-11-15 | GSE84623 | GEO

A Druggable TCF4- and BRD4-dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm (RNA-Seq)

2016-11-15 | GSE84471 | GEO